Back to Search
Start Over
SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells
- Source :
- Cancer Management and Research
- Publication Year :
- 2020
- Publisher :
- Dove, 2020.
-
Abstract
- Dazun Shi, Yu Zhang, Yan Tian Department of Gynecology and Obstetrics, Xiangya Hospital, Central South University, Changsha, Hunan Province, People’s Republic of ChinaCorrespondence: Yan TianDepartment of Gynecology and Obstetrics, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of ChinaEmail tianyxycsu@163.comObjective: The acquisition of chemoresistance to methotrexate (MTX) still remains one of the major challenges for choriocarcinoma treatment. Herein, we aimed to evaluate the potential role of Signaling Lymphocytic Activation Molecule Family Member 1 (SLAMF1) as a possible regulator of chemoresistance to MTX in choriocarcinoma.Material and Methods: MTX-resistant JEG3 and JAR sublines (JEG3/MTX, JAR/MTX) were used to study SLAMF1 function. CCK8 assay and soft agar assay were conducted to measure the cell viability and clonogenesis of choriocarcinoma cells, respectively; MDC incorporation assay was conducted for the quantification of intracellular autophagy; BrdU labeling was used to assess the proliferative potential of choriocarcinoma cells; SLAMF1 protein expression was analyzed by Western blotting.Results: Upregulation of SLAMF1 expression was observed in MTX-resistant JEG3/MTX and JAR/MTX sublines compared to their parental JEG3 and JAR cell lines, respectively. Knockdown of SLAMF1 markedly attenuated cell viability and soft agar clonogenesis after incubation with MTX in JEG3/MTX and JAR/MTX cells. In contrast, constitutive expression of SLAMF1 rescued cell survival soft agar clonogenesis in JEG3 and JAR cells treated with MTX. Moreover, autophagy is apparently activated in MTX-resistant JEG3/MTX and JAR/MTX sublines compared to their parental cell lines. Autophagy inhibitor 3-methyladenine and bafilomycin A1 enhanced MTX-induced cytotoxicity in MTX-resistant JEG3 and JAR sublines. Further, SLAMF1 might activate autophagy-related mechanism to promote resistance to MTX in choriocarcinoma cells. Depletion of SLAMF1 suppressed autophagy and induced apoptosis in MTX-treated JEG3/MTX and JAR/MTX cells.Conclusion: SLAMF1 might promote MTX resistance via activating protective autophagy in choriocarcinoma cell lines. Targeting SLAMF1 might be a useful therapeutic strategy to sensitize choriocarcinoma cells to MTX-based regimens.Keywords: choriocarcinoma, methotrexate, drug resistance, SLAMF1, autophagy
- Subjects :
- 0301 basic medicine
musculoskeletal diseases
autophagy
methotrexate
03 medical and health sciences
0302 clinical medicine
Downregulation and upregulation
immune system diseases
medicine
choriocarcinoma
heterocyclic compounds
Viability assay
Cytotoxicity
skin and connective tissue diseases
Original Research
drug resistance
Chemistry
Autophagy
Choriocarcinoma
medicine.disease
030104 developmental biology
Oncology
Cancer Management and Research
Apoptosis
Cell culture
030220 oncology & carcinogenesis
embryonic structures
Cancer research
Methotrexate
SLAMF1
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 11791322
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Cancer Management and Research
- Accession number :
- edsair.doi.dedup.....16c4c549345b10ba3513d15fd1128f59